Results 61 to 70 of about 206,955 (264)
RT promotes VG161 replication in BC and its immunostimulatory transgenes expression, which is mediated by the upregulation of GADD34 and HVEM caused by RT. The combination therapy with VG161 and RT increases the abundances of tumor‐infiltrating lymphocytes and elicits potent systemic antitumor immunity, thereby effectively inhibiting local tumors and ...
Lijuan Lyu +13 more
wiley +1 more source
CIS of the bladder: a review of literature
Carcinoma in situ (CIS) of the bladder poses a clinical challenge to urologists worldwide. The clinical course of CIS ranges from benign, indolent tumor growth to highly progressive tumor proliferation with deleterious effects on patient outcome and ...
Ahmed Fouad Kotb +2 more
doaj +1 more source
Glioblastoma (GBM) exhibits RFX7 silencing via promoter hypermethylation, which downregulates PIK3IP1 to activate PI3K/AKT signaling, increase lactate accumulation, and enhance histone H4K12 lactylation. This lactylation upregulates PD‐L1/CSF1 expression and drives the immunosuppressive microenvironment formation.
Liying Han +20 more
wiley +1 more source
Consideraciones en patología no invasiva
Hiperplasia epitelial y enfermedad proliferativa. Riesgo relativo de desarrollar cáncer de mama. Carcinoma in situ (estado o (tis nomo). Carcinoma lobulillar in situ (cli). Carcinoma ductal in situ (cd/s). Enfermedad de paget in situ.
Federación Colombiana de Obstetricia y Ginecologia
doaj +1 more source
ABSTRACT Iron overload is a common metabolic disturbance in cancer and contributes to poor outcomes in renal cell carcinoma (RCC), yet its effects on the tumour immune microenvironment remain unclear. Here we identify a previously unrecognized immunosuppressive axis in which iron overload downregulates the palmitoyltransferase ZDHHC12 in CD8+ T cells ...
Xin Jin +16 more
wiley +1 more source
Background and purpose: Breast ductal carcinoma in situ with microinvasion (DCIS-MI) is considered to be the interim stage in the progression from breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).
李 爽, 郎冠天, 余科达
doaj
Carcinoma in situ of the bladder
Abstract Five cases of carcinoma in situ of the urinary bladder are reviewed. The clinical features, difficulties in diagnosis, and surgical management are discussed.
openaire +2 more sources
Tumor‐Infiltrating mregDCs Restrain Anti‐Tumor Immunity in Early Relapse HCC
Tumor‐infiltrating mregDCs are regulated by the TNFR2‐non‐canonical NF‐κB axis, which is mediated by TNF‐α secreted by CD161+CD8+ T cells. These mregDCs recruit CD161+CD8+ T cells via the CCL20‐CCR6 axis, forming a positive feedback loop that enhances immunosuppression, promotes early recurrence of HCC, and further confirms TNFR2 as a key therapeutic ...
Zefan Zhang +13 more
wiley +1 more source
Potential biomarkers of ductal carcinoma in situ progression
Background Ductal carcinoma in situ is a non-obligate precursor of invasive breast carcinoma and presents a potential risk of over or undertreatment. Finding molecular biomarkers of disease progression could allow for more adequate patient treatment.
Raquel Spinassé Dettogni +17 more
doaj +1 more source
ABHD17C‐mediated depalmitoylation of BCL6B at Cys442 blocks its nuclear import and triggers ubiquitin‐dependent degradation, attenuating transcriptional repression of the anti‐phagocytic signal CD24. This mechanism enables pancreatic cancer cells to evade macrophage phagocytosis and fosters an immunosuppressive microenvironment.
Yalu Zhang +9 more
wiley +1 more source

